Market revenue in 2023 | USD 118.8 million |
Market revenue in 2030 | USD 216.3 million |
Growth rate | 8.9% (CAGR from 2023 to 2030) |
Largest segment | Human donor tissue-derived products |
Fastest growing segment | Human Donor Tissue-Derived Products |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Human Donor Tissue-Derived Products, Acellular Animal-derived Products |
Key market players worldwide | 3M Co, Organogenesis Holdings Inc Class A, Integra Lifesciences Holdings Corp, Smith & Nephew PLC, MiMedx Group Inc, Essity AB Class B, Stryker Corp, Vericel Corp, Mallinckrodt PLC Ordinary Shares - New, Tissue Regenix |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biological skin substitutes market will help companies and investors design strategic landscapes.
Human donor tissue-derived products was the largest segment with a revenue share of 66.92% in 2023. Horizon Databook has segmented the U.S. biological skin substitutes market based on human donor tissue-derived products, acellular animal-derived products covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. held the largest market share of 86.54% in North America in 2023. Large medical device companies are outsourcing parts of their regulatory functions, such as report writing & publishing, clinical trial application services, product design, and product maintenance, to regulatory service providers, thereby contributing to the growth of the medical device outsourcing market in the U.S.
These companies are also increasingly inclined toward medical device outsourcing due to the requirement of high maintenance and efficient systems for the management of raw materials, which results in minimizing the overall setup costs.
Moreover, medical device outsourcing helps the company focus on core capabilities, the sharing of associated risks, and improved service delivery, which are pertinent to gaining competitive advantages.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. biological skin substitutes market , including forecasts for subscribers. This country databook contains high-level insights into U.S. biological skin substitutes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account